← Patent-cliff monitor small molecule RISVAN RISPERIDONE
Loss of exclusivity May 2031 latest FDA-listed patent expiry
Drug detail Brand name RISVAN Active ingredient RISPERIDONE Strength 100MG Dosage form FOR SUSPENSION, EXTENDED RELEASE Route INTRAMUSCULAR Modality Small molecule FDA approval March 2024 Marketing status DISCN
Listed patents Patent Expires Type 11752092 May 2031 use U-3941 11241377 May 2031 use U-3939 11173110 May 2031 use U-3941 11007139 May 2031 use U-3942 10195138 May 2031 use U-3943 10182982 May 2031 use U-3943 11759416 May 2031 use U-3939 11752094 May 2031 use U-3942 10881605 May 2031 product 10058504 May 2031 product 10085936 May 2031 product 10463607 May 2031 product 11752093 May 2031 product 10335366 May 2031 product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.